Holen Sie sich die Stockscreener-App
164.11
3.21%
-5.44
Handel nachbörslich:
164.11
Schlusskurs vom Vortag:
$169.55
Offen:
$170
24-Stunden-Volumen:
109.69K
Relative Volume:
0.51
Marktkapitalisierung:
$6.46B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-62.39M
KGV:
-85.48
EPS:
-1.9198
Netto-Cashflow:
-
1W Leistung:
-5.30%
1M Leistung:
-6.36%
6M Leistung:
+136.20%
1J Leistung:
+136.18%
1-Tages-Spanne:
$162.89
$172.71
1-Wochen-Bereich:
$162.89
$181.99
52-Wochen-Spanne:
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
164.11 | 6.67B | 0 | -62.39M | 0 | -1.9198 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.35 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.09 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-26 | Eingeleitet | BofA Securities | Buy |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-02 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Eingeleitet | Mizuho | Neutral |
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - MarketBeat
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
(BLTE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright - MarketBeat
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com
Belite Bio Q4 Earnings Call Highlights - Defense World
Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - MarketBeat
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat
Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com
Earnings call transcript: Belite Bio beats Q4 2025 EPS expectations, stock dips slightly - Investing.com
Belite Bio (NASDAQ:BLTE) Shares Down 8.6%What's Next? - MarketBeat
Belite Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win - TipRanks
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Liquidity Mapping Around (BLTE) Price Events - Stock Traders Daily
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter ... - Caledonian Record
China Universal Asset Management Co. Ltd. Acquires New Position in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Belite Bio, Inc (BLTE) Stock Report: Analyst Ratings Signal Strong Buy with 9.62% Potential Upside - DirectorsTalk Interviews
Darwin Global discloses 8.1% Belite Bio (BLTE) holding in 13G/A - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Sees Large Growth in Short Interest - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January - MarketBeat
Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Belite Bio, Inc (BLTE) Stock Analysis: Biotechnology Innovator With 4.98% Potential Upside - DirectorsTalk Interviews
Belite Bio (NASDAQ:BLTE) Shares Down 5.2%Here's Why - MarketBeat
Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial - Sahm
Belite Bio stock hits all-time high at 177.28 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 177.28 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month HighHere's What Happened - MarketBeat
Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach - Sahm
Understanding Momentum Shifts in (BLTE) - Stock Traders Daily
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com Nigeria
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):